TABLE 2 .
Prognostic impact of biomarker gene signatures in NSCLC patients treated with complete resection with or without ACT
| First author [ref.] | Subjects n | Treatment | Stage | Method | Biomarker | Biomarker expression | Disease-free survival | Overall survival | ||||
| Survival | p-value | Survival | p-value | |||||||||
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| Zhu [31] | 133 | ACT (CDDP + NVB) or OP# | IB–II | RT-PCR | 15-gene signature | High risk | NA | NA | NA | HR: 15.02 (5.12–44.04) | <0.01 | NA |
| Low risk | NA | NA | NA | NA | NA | NA | ||||||
| Chen [32] | 62 | OP | I–III | DNA microarray | 92-gene signature | High risk | NA | NA | NA | 39.2% | 0.01 | NA |
| Low risk | NA | NA | NA | 71.4% | NA | |||||||
| Kratz [33] | 967 only non-SCC | OP | I–III | qPCR | 14-gene signature | High risk | NA | NA | NA | 44.6% | <0.0001 | NA |
| Intermediate risk | NA | NA | NA | 57.4% | NA | |||||||
| Low risk | NA | NA | NA | 74.1% | ||||||||
| Wistuba [34] | 381 | OP | IA–IIB | qPCR | 31-gene signature | High CCP score | HR: 2.10 (1.39–3.17) | 0.00033 | NA | HR: 1.92 (1.18–3.10) | 0.0071 | NA |
| Low CCP score | NA | NA | ||||||||||
Survival data are presented as hazard ratios (HR) (95% CI) or % 5-year survival. NSCLC: nonsmall cell lung cancer; ACT: adjuvant chemotherapy; CDDP: cisplatin; NVB: vinorelbine; OP: complete surgery only; RT-PCR: reverse transcriptase PCR; NA: not available; SCC: squamous cell carcinoma; qPCR: quantitative PCR; CCP: cell cycle progression gene. #: randomised trial, ACT group and OP group (control group).